Nutrient drink beneficial for Alzheimer’s patients, MIT Clinical Trial
A recent clinical trial from MIT has found that the nutrient drink ‘Souvenaid’ is linked to improved memory performance in patients with mild Alzheimer’s disease.
These findings, published in the July 2012 issue of the Journal of Alzheimer’s Disease, were concluded after a 24-week randomised study involving participants across multiple countries led by MIT researchers. This study was designed to extend the work of previous research conducted on the supplement and was successful in confirming earlier findings of a beneficial impact on the cognitive function of individuals diagnosed with Alzheimer’s.
Souvenaid is a nutrient drink intended for medical use and consists of various vitamins and minerals including Vitamin C, Vitamin D, Vitamin B12 and Folic Acid, among others.
Researchers found that consuming Souvenaid had a significant biological impact on the brain as the drink had a positive impact on the formation and functioning of synapses. Poor cognitive function is attributed to a decline in the number of synapses in the brain and so, as suggested by the study, targeting this detrimental brain activity can be an effective avenue of treatment.
Using nutrition as a means to counteract synaptic loss is a new and innovative area of Alzheimer’s research with much potential for future treatment options.
Researchers have encouraged further investigation into the benefits of Souvenaid as a treatment for the early stages of Alzheimer’s.